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Molecular Biology, Hyderabad, India
Boundaries between monogenic and complex genetic diseases are becoming
increasingly blurred, as a result of better understanding of phenotypes and their genetic
determinants. This had a large impact on the way complex disease genetics is now
being investigated. Starting with conventional approaches like familial linkage, positional
cloning and candidate genes strategies, the scope of complex disease genetics has
grown exponentially with scientific and technological advances in recent times. Despite
identification of multiple loci harboring common and rare variants associated with
complex diseases, interpreting and evaluating their functional role has proven to be
difficult. Information from monogenic diseases, especially related to the intermediate
traits associated with complex diseases comes handy. The significant overlap between
traits and phenotypes of monogenic diseases with related complex diseases provides
a platform to understand the disease biology better. In this review, we would discuss
about one such complex disease, type 2 diabetes, which shares marked similarity of
intermediate traits with different forms of monogenic diabetes.
Keywords: simple/Mendelian diseases, complex diseases, type 2 diabetes, monogenic diabetes, maturity onset
diabetes of the young
Introduction
Genetic diseases have been historically categorized into simple, monogenic and complex, polygenic
diseases. This straight forward classiﬁcation of inherited diseases based on the number of
genes involved in precipitating a diseased state proved to be useful in the identiﬁcation and
development of eﬀective diagnostic, genetic counseling strategies, and drug target genes. Studies
on single gene- Mendelian disorders have greatly beneﬁtted our understanding of disease causing
variants, gene functions and various regulatory mechanisms involved in the normal physiological
functioning of the body (Weatherall, 2000). However, this distinction between rare monogenic
and common complex diseases is now unclear with blurring boundaries deﬁning these categories
(Cooper et al., 2013). One of the best examples driving this point is sickle cell anemia which
is caused by single base substitution that replaces glutamic acid with valine in the β-globin
(Ingram, 1957). However, marked clinical heterogeneity cannot be explained by this single
global mutation but to an extent by diﬀerent haplotype background in the gamma-globin
gene (Steinberg, 2005). Interestingly, the diﬀerences among diﬀerent gamma-globin haplotypes
correlate with diﬀerences in mean levels of fetal hemoglobin (HbF), which is known to inﬂuence
the disease severity. Early linkage studies identiﬁed Xmn1-HBG2 and HBS1L-MYB loci and
genome-wide association studies (GWAS) identiﬁed polymorphisms at BCL11A locus, which
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predict higher HbF levels and a milder disease course in sickle
cell anemia patients (Lettre et al., 2008; Sedgewick et al., 2008;
Uda et al., 2008). Together, they account for 20–50% of the
variance in HbF levels, illustrating the importance of other
genetic loci in modifying disease severity (Menzel and Thein,
2009; Thein et al., 2009). Thus, sickle cell anemia, which was
once considered as the simplest of all Mendelian diseases,
now strikes as an example of complex disease where multiple
factors inﬂuence a particular patient’s clinical outcome. The
story of sickle cell anemia highlighting limitations in the age-old
classiﬁcation of inherited diseases doesn’t stand in isolation. This
example can now be extrapolated to other Mendelian disorders
like phenylketonuria, cystic ﬁbrosis etc. where mutations in one
primary gene are present inmost of the cases but the phenotype is
inﬂuenced by allelic heterogeneity and/or mutations at multiple
modiﬁer genes (Dipple and McCabe, 2000a).
In today’s world, genetic diseases represent a continuum
where the phenotype is inﬂuenced by the number of loci
involved and the extent of environmental participation. This
also has direct relation to the methods used for understanding
genetic diseases (Dipple and McCabe, 2000b). Techniques
utilized for investigating single gene disorders may be
applied to identiﬁcation of genes inﬂuencing intermediate
traits related to complex diseases. Similarly, methodologies
typically used for complex trait analysis like GWAS and
next-generation sequencing (NGS) technologies may be
applied for identiﬁcation of modiﬁer genes that inﬂuence
the phenotypes in monogenic disorders. In this review, we
will discuss about one such disease, where defects in single
gene are known to cause relatively rare, monogenic forms of
diabetes and polymorphisms at several loci are associated with
polygenic forms of diabetes. Signiﬁcant overlap of phenotypes
between monogenic diabetes and commonly occurring type
2 diabetes (T2D) provide a great platform to investigate
pathophysiological mechanisms underlying development
of T2D.
Diabetes: A Complex, Chronic Metabolic
Disease
Diabetes is the most prevalent metabolic disease characterized by
hyperglycemia due to primary defects in insulin secretion and/or
insulin function. Diabetes has reached pandemic proportions
with 347 million people aﬀected worldwide which can be traced
back to rapid rise in obesity and life style changes like physical
inactivity (American Diabetes Association, 2014). Inadequate
treatment is potentially devastating due to micro- and macro-
vascular complications. Total deaths due to diabetes is expected
to rise by 50% in the coming decade projecting it to be the
7th leading global cause of death by 2030 (Mathers and Loncar,
2006). High rate of morbidity and mortality in diabetes is due to
the direct and indirect eﬀects of hyperglycemia on the vasculature
which include retinopathy causing loss of vision, nephropathy
causing renal failure, peripheral neuropathy and autonomic
neuropathy and macrovascular complications such as stroke and
atherosclerosis (Forbes and Cooper, 2013).
Majority of diabetic cases are broadly classiﬁed into two
etiological categories: type 1 diabetes (T1D) where lack of
insulin secretion due to auto-immune mediated destruction
of beta cells causes hyperglycemia and T2D where insulin
resistance and inadequate insulin secretory response result in
raised circulating glucose levels (American Diabetes Association,
2014). T1D represents around 5–10% (Atkinson et al., 2014) and
T2D accounts for about 90% of the diabetic cases worldwide
(Wild et al., 2004). Autoimmune destruction of beta cells has
multiple genetic predispositions (Onengut-Gumuscu et al., 2015)
and eﬀect of environmental factors is still being understood
in T1D (Knip et al., 2005; Vaarala et al., 2008). However,
markers of immune destruction like islet cell auto-antibodies,
auto-antibodies to insulin, GAD65, and tyrosine phosphatases
IA-2 and IA-2b and rise in circulating levels of C-peptide
help in reasonably accurate diagnosis of T1D and determine
their clinical course (Arvan et al., 2012; American Diabetes
Association, 2014; Atkinson et al., 2014). In the latter case,
decreased insulin secretion and insulin resistance frequently co-
exist in patients. T2D, on the other hand is characterized by
resistance to insulin action in tissues like liver, skeletal muscle and
adipose tissue, which leads to other features such as dyslipidaemia
and central obesity (Thomas and Philipson, 2015). Impaired
fasting glucose (IFG) or impaired glucose tolerance (IGT) can
provide indications of derangements in glucose metabolism
(American Diabetes Association, 2014). Patients spend a long
asymptomatic period characterized by hyperglycemia, which is
undetectable but suﬃcient to cause pathological changes.
T1D and T2D are polygenic in nature and caused due
to interaction between genetic and environmental factors.
Monogenic diabetes, on the other hand represents rare,
heterogeneous group of disorders due to genetic defects in
single genes causing pancreatic beta cell dysfunction and marked
hyperglycemia (Thomas and Philipson, 2015). Around 2–5% of
global cases correspond to monogenic diabetes. Maturity onset
diabetes of the young (MODY) and neonatal diabetes mellitus
(NDM) represent two diﬀerent classes of monogenic diabetes
where hyperglycemia is either due to defects in insulin secretion,
decrease in beta cell mass or both (Schwitzgebel, 2014). MODY
is characterized by features like autosomal dominant inheritance
pattern, positive familial history, early age of onset, absence of
auto-immune antibodies and insulin resistance (Owen, 2013).
Its shared features (Table 1) with other forms of diabetes often
results in misdiagnosis of MODY patients as T1D or T2D
patients (van der Zwaag et al., 2015). NDM on the other hand
is characterized by onset of hyperglycemia in the ﬁrst few weeks
of life and can be either transient neonatal diabetes mellitus
(TNDM) or permanent neonatal diabetes mellitus (PNDM).
TNDM is a mild form and usually resolves by 18 weeks of age but
the patients are at risk of developing diabetes in the adult stages
of life where as PNDM requires life-long treatment and can result
in isolated hyperglycemia or may present with extra-pancreatic
features depending on the gene mutated (Greeley et al., 2011).
In addition to these categories, few monogenic forms of
insulin resistance such as primary lipodystrophic syndromes and
insulin receptor defects leading to Donahue syndrome, Rabson–
Mendenhall syndrome or Type-A insulin resistance display
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TABLE 1 | Characteristic features of different types of diabetes.
Features Type 1 diabetes (T1D) Type 2 diabetes (T2D) Maturity onset diabetes of the young
(MODY)
Age of onset Any age/more frequent childhood and
adolescence
More frequent in adults and obese
children
Usually before the age of 25 years
Parents affected Rarely multigenerational Rarely multigenerational Usually minimum three generations affected
Inheritance Polygenic Polygenic Monogenic, autosomal dominant/recessive
Beta cell autoantibodies Present Absent Absent
C-peptide Undetectable/low Normal/high Normal
Insulin production Absent Present Present*
Obesity Usually absent Frequent (>80%) Very rare
Diabetic ketoacidosis Common Rare Rare
First line treatment Insulin Oral hypoglycemic agents (Metformin) Depends on sub-type of MODY
*Low levels when pancreatic agenesis occurs due to gene mutations.
features of metabolic syndrome and are associated with insulin
resistant T2D (Hegele, 2003).
Genetics of Monogenic Diabetes: A
Success Story
Linkage studies in families with above diagnostic criteria
identiﬁed mutations in several genes leading to MODY.
Mutations in hepatocyte nuclear factor 4 alpha, (HNF4A,
MODY1), glucokinase (GCK, MODY2), hepatocyte nuclear
factor 1 alpha (HNF1A, MODY3) result in most common forms
of MODY (Shields et al., 2010; Pihoker et al., 2013). Mutations
in genes like pancreatic and duodenal homeobox 1 (PDX1,
MODY4), hepatocyte nuclear factor 1 beta (HNF1B, MODY5)
neurogenic diﬀerentiation 1 (NEUROD1, MODY6) and insulin
(INS, MODY10) cause relatively rare forms of MODY (Naylor
and Philipson, 2011). Fine mapping studies and the advent of
NGS technologies like whole-exome sequencing, not only rapidly
increased themutational spectrum of causal genes but also helped
in the identiﬁcation of novel MODY genes (Bamshad et al., 2011;
Ku et al., 2011; Bonnefond et al., 2012; Johansson et al., 2012).
Currently, Online Mendelian Inheritance in Man (OMIM) lists
13 diﬀerent causal genes that result in distinct sub-phenotypes of
MODY as described in Table 2.
TNDM is most commonly caused due to over-expression of
imprinted genes, PLAGL1 and HYMAI at 6q24 due to paternal
uniparental disomy of chromosome 6 or duplication of 6q24
on the paternally inherited allele or hypomethylation of the
maternally inherited 6q24 allele (Temple and Shield, 2002).
Other rarer causes of TNDM include heterozygous mutations in
genes encoding sub-units of ATP-sensitive potassium channel:
potassium channel, inwardly rectifying subfamily J, member 11
(KCNJ11) (Flanagan et al., 2007), ATP-binding cassette, sub-
family C, member 8 (ABCC8) (Patch et al., 2007) and bi-allelic
mutations in zinc ﬁnger protein 57 (ZFP57) (Mackay et al.,
2008). In addition, rare mutations in INS may also cause a
phenotype which can be described as TNDM (Stoy et al., 2007).
More than 50% of PNDM cases are due to activating mutations
in KCNJ11 and ABCC8, while majority of mutations genes
associated with PNDM are de novo in origin (Gloyn et al., 2004;
Babenko et al., 2006; Edghill et al., 2010). Approximately 20%
of PNDM is attributed to mutations of INS (Stoy et al., 2007).
Rarely PNDM is caused by inactivating mutations of PDX1 and
glucose transporter2 (SLC2A2) (Nicolino et al., 2010). As of date,
mutations in close to 20 genes are known to cause diabetes in the
ﬁrst year of life (Table 2).
Hyperglycemia is a common consequence of mutations in
these genes; nevertheless, they are associated with distinct
phenotype and characteristic clinical presentation. For instance,
mutations in HNF4A are associated with increase in birth
weight, macrosomia, hypoglycemia at birth and adolescent onset
of diabetes (Pearson et al., 2007). Patients exhibit progressive
beta cell failure and long term treatment with low dose
sulphonylureas is proven to be more eﬀective than insulin
treatment (Fajans and Brown, 1993). In addition to the above
features, patients carryingHNF-1Amutations present with severe
dysfunction of hepatocytes and renal tubular cells resulting
in glycosuria with high incidence of vascular complications.
Patients with HNF1A mutations are also extremely sensitive to
low doses of sulphonylureas (Pearson et al., 2000). Mutations
in HNF1B are associated with renal defects with cystic renal
disease, pancreatic agenesis and genitor-urinary abnormalities.
But these patients are insensitive to treatment with insulin
sensitizers and require early treatment with insulin (Edghill
et al., 2006). In contrast to the mutations in various HNF
genes, glucokinase mutations result in mild, stable, fasting
hyperglycemia from birth and small elevations in post-prandial
glucose levels. Insulin secretion remains intact and vascular
complications are not commonly observed in these patients and
hence they do not require any pharmacological intervention
and dietary intervention is usually suﬃcient to maintain stable
glycosylated hemoglobin levels (HbA1c) levels (Stride et al., 2002;
Murphy et al., 2008). ActivatingKCNJ11mutations are associated
with a number of clinical features ranging from isolated
diabetes to more severe phenotypes such as developmental
delay-epilepsy-neonatal diabetes syndrome (Gloyn et al., 2006).
Neonatal patients identiﬁed with KCNJ11 and ABCC8mutations
show little endogenous insulin secretion and non-detectable
C-peptide levels and hence used to be put on long-term insulin
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treatment. However, understanding of mechanism of action
of sulphonylureas led to shift of therapeutic regimen from
insulin injections to high sulphonylureas with improved glycemic
control, lower costs of treatment and better quality of life (Sagen
et al., 2004; Pearson et al., 2006; Mlynarski et al., 2007; Raﬁq et al.,
2008). This stands as a classical example of application of genetic
information for personalized medicine.
The success in the ﬁeld of monogenic diabetes can largely
be attributed to a distinct phenotype associated with each sub-
class, and strong genotype-phenotype correlation that allowed
room for better diagnostic- and genotype- based management
options. Genetic dissection of diﬀerent forms of monogenic
diabetes sheds light on beta cell physiology and improved
understanding of insulin secretion and its regulation. With
rapid advances and decreased cost of the NGS technologies, it
is expected that screening of people aﬀected with monogenic
diabetes would unravel novel genetic etiologies of pancreatic beta
cell dysfunction (Bamshad et al., 2011; Ellard et al., 2013).
Type 2 Diabetes Is a Syndrome, Not a
Single Disease
From the above section, it is evident that monogenic diabetes
has a clear genetic basis and a reasonably distinct phenotypic
presentation for each sub-class. T1D also has clear autoimmune
origin leading to absolute insulin deﬁciency in vast proportion of
cases. These facts have guided beneﬁts of early intensive glycemic
control (HbA1c below 6%) compared to conventional approach
(HbA1c between 7 and 7.9%) in T1D patients as demonstrated in
Diabetes Control and Complications Trial (DCCT) and follow-
up Epidemiology of Diabetes Interventions and Complications
(EDIC) clinical trials which showed signiﬁcant reduction in the
risk of developing both micro and macrovascular complications
associated with chronic hyperglycemia (Diabetes Control and
Complications Trial, 2005).
In a sharp contrast, T2D does not have a known directly
identiﬁable cause. It is characterized by progressive insulin
resistance in insulin responsive tissues, dyslipidaemia, abdominal
obesity, and rise in pro-coagulant and pro-inﬂammatory factors
(Thomas and Philipson, 2015).Multitude of studies have revealed
the confounding eﬀects of risk factors like age, sex, physical
inactivity, smoking, diet, ethnicity, family history, and gestation.
Adding to the complexity, chronic exposure to stress, low socio-
economic status and psycho-social factors are also shown to be
risk factors for T2D from recent environment-wide association
studies. The diagnosis of T2D can rather be considered “waste
basket diagnosis”—not because there is no-cause, but because
there is no-one-cause. The rate of disease progression and advent
of long-term complications is not similar in all patients and
hence treatment regimen needs individual tailoring based on
suitable assessment of risk factors involved. While follow-up of
United Kingdom Prospective Diabetes Study (UKPDS) showed
that tight glycemic control decreases macrovascular end points
in patients with T2D (Group UKPDS, 1998), other studies like
Action to Control Cardiovascular Risk in Diabetes (ACCORD)
and Action in Diabetes and Vascular Disease (ADVANCE) trials
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did not provide consistent results. Type 2 diabetics with intensive
blood glucose-lowering treatment arm had an increased risk of
cardiovascular death in ACCORD trial compared to those in the
conventional treatment arm (Ismail-Beigi et al., 2011). Although
the ADVANCE trial did not exhibit increased mortality, it did
not reveal any signiﬁcant beneﬁt on macrovascular outcome
(Zoungas et al., 2009). All these observations strongly indicate
that T2D is not a single disease, but, a conglomeration of
metabolic disorders characterized by a combination of multiple
intermediate traits like increased IFG, IGT, body mass index
(BMI), waist-hip-ratio (WHR), dyslipidemia and hypertension.
This very reason led to a paradigm shift in the ﬁeld of genetics of
T2D, which is discussed in detail in the next section.
Genetics of Type 2 Diabetes: An
Unexpected Failure or a Missed
Opportunity
Several lines of evidence support the principle of inherited
genetic susceptibility as an important risk factor for T2D.
Oﬀspring of a parent with T2D face a 40% lifetime risk of
developing T2D, which increases to 70% when both parents
have T2D. High concordance rate obtained in monozygotic
twins (96%) suggests a strong genetic component of this multi-
factorial disease (Barnett et al., 1981). Furthermore, 40% of ﬁrst-
degree relatives of T2D patients develop diabetes as compared to
6% in the general population (Kobberling and Tillil, 1982). Its
substantial genetic component propelled geneticists from all over
the globe to devote huge eﬀorts for the hunt of T2D susceptibility
genes.
Initial attempts were through genome-wide familial
linkage-based approaches using multi-generational pedigrees
and/or aﬀected sib-pairs studies where the analysis relies
on shared chromosomal regions inherited from common
ancestors to identify familial genetic variants with large
consequences. While this method largely helped in genetic
studies of monogenic diabetes, its application to common
T2D has been a limited success. Several chromosomal regions
showed evidence of linkage, but positional cloning of the
putative causative genes has not been successful for most of
the regions except few like HNF4A, calpain 10 (CAPN10),
ectonucleotidepyrophosphatase/phosphodiesterase 1 (ENPP1),
adiponectin, C1Q and collagen domain containing (ADIPOQ)
and transcription factor 7 like 2 (TCF7L2) (Florez et al.,
2003). Parallel to linkage studies, candidate gene approach was
employed by researchers to identify T2D risk associated genes.
Selection of candidate genes was typically based on hypothesis
about biological mechanisms that are putatively involved in T2D
pathogenesis, hence, it was plausible to conceive that variants
in these genes could predispose to disease or related phenotype.
Genes inﬂuencing pancreatic beta cell function, like ABCC8,
KCNJ11, SLC2A2, HNF4A, INS, and genes inﬂuencing insulin
action like PPARG, INSR, PIK3R1, IRS1, IRS2, and SOS1 were
among the initially identiﬁed candidate genes that signiﬁcantly
alter disease susceptibility (McCarthy, 2004). Despite many
positive reports, associations could be replicated rarely in other
studies mainly because of the small sample sizes used in these
studies. Furthermore, poor functional characterization of much
of the genome made it impossible to make fully informed
decisions while selecting candidate genes for association studies.
At this instance, completion of the Human Genome and
International HapMap Projects came as a major boon to the then
growing ﬁeld of T2D genetics. Identifying genetic associations in
a genomic fashion i.e., GWAS became a reality. Based on the
“common variant- common disease (CVCD) hypothesis” that
the genetic risk for common complex diseases is often due to
disease producing alleles found at relatively high frequencies
(>1%), GWA studies were designed to pick upmultiple common
variants associated with disease risk (Reich and Lander, 2001).
The ﬁrst wave of GWAS was conducted in Europeans and
identiﬁed a dozen loci, of which 8 T2D susceptibility loci have
been replicated acrossmultiple ethnic groups:TCF7L2, SLC30A8,
HHEX, CDKAL1, IGF2BP2, CDKN2A/B, PPARG, and KCNJ11
(Cauchi et al., 2007; Lee et al., 2008; Ng et al., 2008; Wu et al.,
2008; Hu et al., 2009; Rong et al., 2009; Chauhan et al., 2010;
Han et al., 2010). In parallel, strong association between FTO
variants and T2D was replicated in three independent studies,
but the association signal weakened after adjustment for BMI,
suggesting that variants mediate risk partly through increased
adiposity (Dina et al., 2007; Frayling et al., 2007; Scuteri et al.,
2007). While the ﬁrst wave of studies employed logistic analyses
and investigated T2D as a dichotomous phenotype in cases and
controls, the second wave of GWAS loci were identiﬁed from
linear analysis of continuous glycemic traits and anthropometric
traits in participants without diabetes. Diﬀerent consortia were
formed to increase the sample size, which facilitated detection of
low-eﬀect common variants associated with T2D risk. One of the
early consortiums was the DIAbetes Genetics Replication And
Meta-analysis consortium (DIAGRAM) aimed at characterizing
genetic basis of T2D, mainly in individuals of European descent
and identiﬁed 31 novel loci associated with increased T2D risk
(Saxena et al., 2007; Sladek et al., 2007; Zeggini et al., 2008;
Voight et al., 2010; Morris et al., 2012; Scott et al., 2012).
Another major collaborative eﬀort to dissect loci that impact
glycemic and metabolic traits was the Meta-Analyses of Glucose
and Insulin-related traits Consortium (MAGIC). Several loci
inﬂuencing traits like fasting plasma glucose (FPG), fasting
insulin, 2h glucose and HbA1c were identiﬁed and many of
them like ADCY5, PROX1, GCK, GCKR, and DGKB-TMEM195
also inﬂuenced risk of T2D (Dupuis et al., 2010; Soranzo et al.,
2010; Strawbridge et al., 2010; Manning et al., 2012; Scott
et al., 2012). The Genetic Investigation of ANthropometric Traits
(GIANT) consortium dedicated eﬀorts to identify genetic loci
that modulate obesity related traits like height, BMI, WHR,
WHR adjusted for BMI and waist and hip circumference. So
far, common genetic variants at hundreds of loci associated with
above anthropometric traits have been identiﬁed (Berndt et al.,
2013; Randall et al., 2013; Locke et al., 2015; Shungin et al., 2015).
In parallel to these studies, GWAS and meta-analyses of
GWAS performed in other ethnicities (i.e., East Asians, South
Asians, and African Americans) revealed multiple new T2D-
associated genes (Billings and Florez, 2010). For example, six
novel signals GRB14, ST6GAL1, VPS26A, HMG20A, AP3S2, and
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HNF4A loci were identiﬁed from a meta-analysis of GWAS
in South Asian population (Kooner et al., 2011). Interestingly,
many, but not all of the variants identiﬁed in Europeans have
been replicated in non-Europeans and amongst the replicated
loci, diﬀerences in allelic frequencies and eﬀect sizes have been
observed (Yajnik et al., 2009). Put together, these results highlight
similarity in genetic susceptibility as well as ethnic diﬀerences
indicating that genetic variability strongly inﬂuences magnitude
of the eﬀect of GWAS risk loci in diﬀerent populations. Adding
to the complexity, amongst close to 80 loci associated with
T2D risk (Data Sheet 3 in Supplementary Material), other than
TCF7L2, there is absence of any large single-gene eﬀects (Billings
and Florez, 2010). Together these loci account for less than
20% of the T2D heritability due to their small eﬀect sizes and
point to reasons for the “missing heritability” in T2D (Manolio
et al., 2009). Furthermore, resolving functional mechanism of
the genetic association and establishing causality has proven
to be extremely challenging, primarily because of the fact that
large percentage of associations are determined by non-coding
variants. This hugely supported the notion that high-penetrant
rare-variants (minor allele frequency<1%) could be the primary
players in common diseases and may have a strong impact on
disease risk (Pritchard and Cox, 2002; Carlson et al., 2004).
While GWAS have implicated previously unknown genes
and pathways in T2D pathogenesis, next generation sequencing
studies like whole genome and exome sequencing aimed at
identifying variants of low frequency with large eﬀect size
and likely elucidate disease causing mechanisms (Cirulli and
Goldstein, 2010; Steinthorsdottir et al., 2014). Whole genome
sequencing of Icelanders has identiﬁed low-frequency and
rare sequence variants in CCDN2, PAM and PDX1 that are
associated with altered T2D risk (Flannick et al., 2014). Similarly,
genotyping of ∼150,000 individuals across 5 ancestry groups
has identiﬁed 12 loss of function mutations in SLC30A8 which
decrease risk of T2D (Majithia et al., 2014).Exome sequencing of
PPARG in 19,752 T2D cases and controls from multiple studies
and ethnic groups identiﬁed rare variants which are associated
with decreased activity in adipocyte diﬀerentiation and increased
T2D risk (Claussnitzer et al., 2014). While these technologies
identify additional genetic changes that contribute to risk of T2D,
obtaining a huge sample size for the detection of low frequency
variants remains a huge challenge.
MODY and T2D: Common Loci-Common
Mechanisms
The GWAS and post-GWAS era witnessed tremendous
advancements made on the technological front and parallel
developments in statistical methodology and inference,
analytical frameworks, and computational tools, yet translation
of the research ﬁndings for accurate risk prediction and
subsequent disease prevention, discovery of new drug targets,
personalization of medicine remains an unsolved challenge.
Increasing eﬀorts are now being devoted to understand the
functional mechanisms underlying genetic association of loci
with T2D risk and associated quantitative glycemic and/or
anthropometric traits. Owing to the large number of associations
found with genetic variants in the non-protein coding region
or gene desert regions, special focus is laid on decoding the
nature of these non-coding variants (Fogarty et al., 2014).
Recent ﬁne mapping and functional characterization of GWAS
variants provide several evidences where cis-regulation is a
common mechanism underlying these associations and most
frequently aﬀected elements include transcriptional enhancers
and silencers (Winckler et al., 2007; Fogarty et al., 2013, 2014).
Thus, identiﬁcation of target genes of cis-regulatory variants is
necessary to understand the functional mechanisms by which
these variants act.
As these eﬀorts continue, gaining novel insights from the
molecular genetics of monogenic forms of diabetes would help
propel research in the ﬁeld of common T2D genetics toward
a translational level. From the research eﬀorts in identifying
genes responsible for monogenic forms of diabetes and ﬁndings
from GWAS for T2D, strong evidence has emerged that several
loci implicated in monogenic diabetes are also involved in
mediating risk of polygenic T2D. As a matter of fact, most of
the T2D susceptibility genes identiﬁed in the pre-GWAS era are
key players in the development of some forms of monogenic
diabetes; KCNJ11, HNF4A, SLC2A2, PPARG, and INSR. Recent
studies identiﬁed few other monogenic diabetes loci likeHNF1A,
HNF1B, GCK, PDX1, GLIS3, WFS1, PAX4, and LMNA which
harbor variants associated with T2D risk (Sidransky, 2006;
Sandhu et al., 2007; Wegner et al., 2007; Voight et al., 2010; Rees
et al., 2011; Cho et al., 2012). Interestingly, several variants in
these loci inﬂuence intermediate glycemic and anthropometric
traits associated with T2D like FPG, insulin related traits, lipid
related traits, Hb1Ac levels, C-reactive protein, homocysteine
and waist circumference. Complete list of loci common between
T2D and monogenic diabetes and associated phenotypes is
presented in Table 3.
It is interesting to observe that loci common/shared
between monogenic diabetes and T2D aﬀect physiological
processes like pancreatic beta cell development and function,
glucose sensing mechanisms and their coupling with insulin
release/secretion and endoplasmic reticulum (ER) stress. Most
of the common loci are transcription factors, which play key
role in beta cell development. For example, PDX1 directs the
early embryonic development of pancreas and diﬀerentiation
of insulin-producing islet β cells in endocrine pancreas by
forming cross-regulatory transcriptional networks where FOXA2
and HNF1B, other T2D associated genes are also key players
(Oliver-Krasinski et al., 2009; Arda et al., 2013). It also promotes
expression of INS, SLC2A2, and GCK, which are essential for
insulin synthesis and glucose sensing. HNF1A also controls beta
cell function by regulating target genes like SLC2A2, HNF4A,
pyruvate kinase, and hepatocyte growth factor activator (Servitja
et al., 2009). Genes encoding ATP-sensitive potassium channel
sub-units KCNJ11 and ABCC8 couple cell metabolism with
membrane potential and play a central role in regulation of
insulin secretion in pancreatic beta cells. Mutations in these
genes form high-risk haplotype which aﬀect progression from
IGT to T2D (Laukkanen et al., 2004). WFS1 forms component
of unfolded protein response and maintains homeostasis of the
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TABLE 3 | Genes/loci common between monogenic diabetes and type 2 diabetes and related intermediate traits.
Genes/loci Trait SNP(s) Nature of variant PubMed IDs
GLIS3 FPG and FPG levels adjusted for BMI rs7034200 Intronic 22581228, 20081858
HOMA-B rs7034200 Intronic 20081858
HNF1A Cholesterol, total rs1169288, rs1800961 Missense 20686565
LDL cholesterol rs1169288, rs2650000 Missense 24097068, 19060906
Homocysteine levels rs2251468 Intronic 23824729
C-reactive protein rs1183910, rs7979473,
rs7310409, rs2393791,
rs2259816, rs7305618
Intronic 23844046, 22939635,
21647738, 21196492,
19567438, 18439548,
24763700
rs1169310 3′ UTR 18439552
HNF4A Cholesterol, total rs1800961 Missense 24097068, 20686565
HDL cholesterol rs1800961 Missense 24097068, 19060906,
24097068
C-reactive protein rs1800961 Missense 21300955, 22939635
GCK FPG rs4607517, rs1799884,
rs3757840
Intronic 19060907, 20081858,
23575436, 22399527
FPG adjusted for BMI rs4607517, rs2293941 Intronic 22581228
1-h plasma glucose and 2-h plasma glucose rs1799884 Intronic 23575436
Glycated hemoglobin levels rs1799884, rs730497,
rs4607517
Intronic 24647736, 24244560,
20858683, 19096518
HOMA-B rs4607517 Intronic 20081858
PPARG Fasting insulin adjusted for BMI rs1801282 Missense 22581228
WHR adjusted for BMI in women rs4684854 Intergenic 23754948
LMNA Cholesterol, total rs577492 Intronic 17327437
Waist circumference rs11578696, rs955383 Intronic 17327437
SLC2A2 FPG and FPG levels adjusted for BMI rs11920090 Intronic 20081858, 22581228
HOMA-B rs11920090 Intronic 20081858
INSR Triglycerides rs7248104 Intronic 24097068
SNP, single nucleotide polymorphism; FPG,Fasting plasma glucose; PG, plasma glucose; BMI, body mass index; HOMA-B, homeostasis model assessment of beta cell function; LDL,
low density lipoprotein; HDL, high density lipoprotein; UTR, untranslated region; WHR, waist-hip ratio.
ER in pancreatic beta cells. Inactivatingmutations inWFS1 result
in ER stress causing beta cell dysfunction and recently HNF4A
is also shown to regulate beta cell susceptibility to ER stress
(Fonseca et al., 2005; Takei et al., 2006).
Deciphering a role for genes implicated inmonogenic diabetes
to T2D has the advantage of carrying the beneﬁts along with.
For example, GCK gene product, hexokinase 4 catalyzes the
ﬁrst step of glycolysis and is expressed in both hepatocytes
and pancreatic beta cells. The beta cell isoform is a glucose
sensor and plays an important role in glucose stimulated insulin
secretion (Matschinsky, 1990, 2002). Common variants in GCK
predict T2D risk by inﬂuencing various T2D intermediate
phenotypes like FPG, HbA1c levels, and HOMA-B (Dupuis
et al., 2010; Soranzo et al., 2010; Manning et al., 2012; Chen
et al., 2013). A recent study has revealed that patients harboring
GCK mutations reportedly have a low prevalence of vascular
complications highlighting the probable limited role of isolated,
mild hyperglycemia in mediating diabetic vascular complications
(Steele et al., 2014). In this scenario, it may not be unreasonable to
surmise a possible role for variants in GCK or other monogenic
diabetes associated genes modifying the T2D disease course in
presence of other precipitating factors. However, it is important
to note that these common loci are causal in case of monogenic
diabetes, yet they contribute merely to T2D pathogenesis and
this discrepancy is largely explained by mutational heterogeneity
and the nature of variants at these loci (Sidransky, 2006). While
mostly, coding and rare variants cause monogenic diabetes, non-
coding and regulatory variants at the same loci are associated
with T2D and related intermediate traits. This, in turn, also
accounts for diﬀerences in the eﬀect sizes of associated variants
and phenotypic heterogeneity between monogenic diabetes and
T2D. Regulatory nature of variants associated with T2D and
intermediate traits also entails gene-gene and gene-environment
interactions, of which the later mainly results in modulation of
variant eﬀects with various factors like physical activity, nutrition,
stress, etc. (Buil et al., 2015). Thus, in contrast to the monogenic
diabetes, screening for the common variants in these loci to
decide the clinical course of T2D is still a long sought dream.
Role of Environmental Factors: Epigenetic
Regulation of Candidate Genes
Epigenetic mechanisms like DNA methylation, covalent histone
modiﬁcations, non-coding RNAs, microRNAs are plausible
means by which environmental factors integrate their eﬀects with
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genetic variants to mediate T2D risk (Ling and Groop, 2009;
Waki et al., 2012). Of all, the most thoroughly studied epigenetic
modiﬁcation is the methylation of cytosine-phosphatidyl-
guanine (CpG) sites which is associated with post-translational
histone modiﬁcations and results in altered chromatin structure
and consequent diﬀerences in gene expression (Jaenisch and
Bird, 2003). The loci shared between monogenic diabetes
and T2D serve as good example to study these interactions.
Mutations in transcription factors like HNF1A, HNF1B, HNF4A,
PDX1, and NEUROD1 modulate their aﬃnity for both histone
modifying enzymes and DNA leading to disruption of regulatory
interactions (Ling and Groop, 2009). Several T2D associated
variants either introduce or remove a CpG site, which results
in diﬀerential DNA methylation and altered expression of
associated or near-by genes. Tissue speciﬁc DNA methylation
of common loci like PPARG, WFS1, IRS1, PDX1, and INS have
been reported in independent studies (Dayeh et al., 2013; Nilsson
et al., 2014). For example, diﬀerential methylation has been
observed in common loci like PPARG and IRS1 in adipose tissue
from unrelated T2D patients compared with control individuals
and expression of PDX1 and INS was decreased in pancreatic
islets from diabetics compared to non-diabetic donors (Yang
et al., 2011, 2012). Interestingly, quantitative DNA methylation
analysis also shows consistent diﬀerences in DNA methylation
patterns between populations of diﬀerent ethnicities at common
loci KCNJ11 along with other loci like ADCY5 and FTO which
are attributed to genetic and/or region-speciﬁc environmental
factors (Elliott et al., 2013).
In addition, epigenetic modiﬁcations are proposed as key
mechanisms in mediating eﬀect of nutritional disturbances that
result in fetal programming and/or metabolic programming
for future risk of cardio-metabolic disorders and is current
topic of scientiﬁc probity. The fetal environment is inﬂuenced
by several factors and maternal under and/or over nutrition,
and interaction between fetal and maternal environment were
found as major determinants mediating metabolic programming
(Aagaard-Tillery et al., 2008; Yajnik and Deshmukh, 2012).
Several epidemiological and animal studies provide evidence for
impact of suboptimal uterine environment and early neonatal
life on the oﬀspring susceptibility to chronic diseases like
T2D in adult life (Snoeck et al., 1990; Breier et al., 2001;
Ozanne and Hales, 2002). Epigenetic mechanisms, especially
changes in DNA methylation have been shown to modulate
eﬀect of these determinants on the altered expression of key
genes involved in fetal metabolism and development (Burdge
et al., 2007; Gonzalez-Bulnes and Ovilo, 2011). The critical
issue is that fetal programming is even transmitted to the
next generations highlighting the possibility of transgenerational
epigenetic inheritance of disease susceptibility (Waki et al., 2012).
Studies on human cord blood samples from neonates with
intrauterine growth restriction due to maternal low protein diet
has shown dysregulation of HNF4A methylation and other loci
encoding HNF4A-interacting proteins (Sandovici et al., 2011).
Similarly, maternal and paternal high fat diet consumption is
associated with global methylation changes and induces glucose
intolerance and insulin resistance in oﬀspring (Aagaard-Tillery
et al., 2008; Gallou-Kabani et al., 2010; Ng et al., 2010). Eﬀect
of maternal micronutrients like folic acid (FA) and vitamin
B12 (B12) on fetal development and increased obesity risk is
already established (Yajnik et al., 2008). Maternal micronutrient
deﬁciency (FA and vitamin B12) results in global methylation
changes in livers of pups leading to decrease in expression of
PPARα and PPARγ genes and supplementation of omega-3 fatty
acid to these pups reduced the global DNA methylation and
restored the expression of these transcription factors highlighting
the role of poly unsaturated fatty acids and their interaction
with one-carbon metabolism (Kulkarni et al., 2011). All the
above results indicate strong role of epigenetic modiﬁcations
not only in mediating the eﬀects of common variants in shared
loci but also in programming fetus for future risk of metabolic
disturbances.
Future Perspectives
Developments in the ﬁeld of T2D genetics have undoubtedly led
to identiﬁcation of new loci like GLIS3 (Cho et al., 2012), PAX4
(Ma et al., 2013), and GCK (Muller et al., 2014) that are common
between monogenic diabetes and T2D. However, expanding
mutational spectrum of these common loci using techniques
like whole exome sequencing has now reached a point of
saturation. At this point, understanding intricate mechanisms of
interaction of these common variants with environmental factors
in manifesting a syndrome like T2D would help us expand basis
of phenotypic heterogeneity in the background of mutational
heterogeneity. A recent study provides experimental evidence
for a new functional approach to investigate epigenetics of T2D
(Fogarty et al., 2014). Epigenetic conservation of dysregulated
loci in high fat diet fed mice and obese humans as observed in
this study substantiates usage of animal models to understand
eﬀect of various environmental factors in modifying disease
risk. Moreover, overlap between epigenetically regulated regions
with nominally associated T2D risk loci suggests that present
approach can complement human genetic studies to assess
clinical risk of such loci. Besides mediating epigenetic changes,
variants in these common loci also explain signiﬁcant proportion
of variance in response to treatment options currently available
for T2D. KCNJ11 and PPARG variants provide evidence of
a successful pharmacogenetic approach for treatment of T2D
(Gloyn et al., 2001; Bluher et al., 2003). Several common
polymorphisms in genes like KCNJ11, ABCC8, WFS1, GLIS3,
HNF4A, HNF1B and GCK that have common antecedents
in monogenetic diabetes and T2D have inﬂuence on the
glycemic outcomes of metformin treatment (Jablonski et al.,
2010). Common variants in KCNJ11, ABCC8, NEUROD1 and
PAX4 predict response to repaglinide for glycemic outcomes
like glycated hemoglobin, fasting glucose and post-prandial
glucose (He et al., 2008; Florez et al., 2012; Gong et al.,
2012). Though, these examples foster the potential for utilization
of these variants in common loci to personalize medicine,
understanding diversity of drug responders, metabolic and
signaling pathways associated with a drug’s action supported
by clinical observations is required for tailoring therapeutic
needs. In addition, exploring new avenues like brain centered
glucose regulation and investigating the role of common loci
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in central regulation of glucose metabolism would help us
expand our horizons and improve our understanding of disease
biology.
Conclusions
To conclude, no genetic disease is monogenetic now, thanks
to better understanding of the clinical phenotype and to the
various technological advances that allow the whole “OME” to
be investigated. Understanding and utilization of single gene
eﬀects on speciﬁc traits that conglomerate into a complex
phenotype is currently the best way to understand the genetic
basis at functional level and be of any use for disease prevention
and management. However, lot of factors such as mutational
heterogeneity, nature of variants, ethnic diﬀerences etc. need to
be understood before this becomes a practical reality.
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